MYL2 and ovarian carcinoma: Next, we chose siRNA CDC42 and blebbistatin, the myosin II ATPase inhibitor, to investigate the role of the CDC42/PAK/MLC2 signaling pathway in regulating ovarian cancer cell stiffness.